Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics
- PMID: 25341010
- PMCID: PMC4428310
- DOI: 10.1146/annurev-med-053013-062946
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics
Abstract
Ketamine is the prototype for a new generation of glutamate-based antidepressants that rapidly alleviate depression within hours of treatment. Over the past decade, there has been replicated evidence demonstrating the rapid and potent antidepressant effects of ketamine in treatment-resistant depression. Moreover, preclinical and biomarker studies have begun to elucidate the mechanism underlying the rapid antidepressant effects of ketamine, offering a new window into the biology of depression and identifying a plethora of potential treatment targets. This article discusses the efficacy, safety, and tolerability of ketamine, summarizes the neurobiology of depression, reviews the mechanisms underlying the rapid antidepressant effects of ketamine, and discusses the prospects for next-generation rapid-acting antidepressants.
Keywords: BDNF; biomarker; depression; mTOR; synaptic plasticity.
Figures



Similar articles
-
NMDA antagonist treatment of depression.Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Curr Opin Neurobiol. 2016. PMID: 26687375 Review.
-
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.Neuropharmacology. 2016 Jan;100:17-26. doi: 10.1016/j.neuropharm.2015.07.028. Epub 2015 Jul 26. Neuropharmacology. 2016. PMID: 26211972 Review.
-
Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.Transl Psychiatry. 2016 Sep 20;6(9):e894. doi: 10.1038/tp.2016.145. Transl Psychiatry. 2016. PMID: 27648916 Free PMC article.
-
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.Behav Brain Res. 2020 Apr 20;384:112548. doi: 10.1016/j.bbr.2020.112548. Epub 2020 Feb 13. Behav Brain Res. 2020. PMID: 32061748 Free PMC article. Review.
-
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17. Am J Psychiatry. 2021. PMID: 33726522 Free PMC article. Review.
Cited by
-
Advances in novel molecular targets for antidepressants.Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jan 10;104:110041. doi: 10.1016/j.pnpbp.2020.110041. Epub 2020 Jul 16. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 32682872 Free PMC article. Review.
-
Rapid-Onset Antidepressant-Like Effect of Nelumbinis semen in Social Hierarchy Stress Model of Depression.Evid Based Complement Alternat Med. 2022 May 29;2022:6897359. doi: 10.1155/2022/6897359. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35677378 Free PMC article.
-
FMOD Alleviates Depression-Like Behaviors by Targeting the PI3K/AKT/mTOR Signaling After Traumatic Brain Injury.Neuromolecular Med. 2024 Jun 12;26(1):24. doi: 10.1007/s12017-024-08793-2. Neuromolecular Med. 2024. PMID: 38864941 Free PMC article.
-
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.Neuron. 2019 Jan 16;101(2):307-320.e6. doi: 10.1016/j.neuron.2018.11.021. Epub 2018 Dec 4. Neuron. 2019. PMID: 30528065 Free PMC article.
-
Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks.Sci Rep. 2019 Aug 7;9(1):11484. doi: 10.1038/s41598-019-46702-x. Sci Rep. 2019. PMID: 31391479 Free PMC article. Clinical Trial.
References
LITERATURE CITED
-
- Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
-
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17. - PubMed
-
- Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566–79. - PubMed
-
- Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–54. - PubMed
RELATED RESOURCES
-
- Bading H. Nuclear calcium signalling in the regulation of brain function. Nat Rev Neurosci. 2013;14:593–608. - PubMed
-
- Gladding CM, Raymond LA. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci. 2011;48:308–20. - PubMed
-
- Hardingham GE, Bading H. The yin and yang of NMDA receptor signalling. Trends Neurosci. 2003;26:81–89. - PubMed
-
- Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169:1150–56. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous